Share

December 04, 2012; 79 (23) Article

Orexin receptor antagonism for treatment of insomnia

A randomized clinical trial of suvorexant

W. Joseph Herring, Ellen Snyder, Kerry Budd, Jill Hutzelmann, Duane Snavely, Kenneth Liu, Christopher Lines, Thomas Roth, David Michelson
First published November 28, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31827688ee
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1262

Share

Article Information

vol. 79 no. 23 2265-2274
DOI: 
https://doi.org/10.1212/WNL.0b013e31827688ee
PubMed: 
23197752
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 5, 2012
  • Accepted July 30, 2012
  • First Published November 28, 2012.

Article Versions

Copyright & Usage: 
© 2012 American Academy of Neurology

Author Disclosures

    1. W. Joseph Herring, MD, PhD,
    2. Ellen Snyder, PhD,
    3. Kerry Budd, BS,
    4. Jill Hutzelmann, MS,
    5. Duane Snavely, MA,
    6. Kenneth Liu, PhD,
    7. Christopher Lines, PhD,
    8. Thomas Roth, PhD and
    9. David Michelson, MD
  1. W. Joseph Herring, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck, Executive Director Clinical Neuroscience

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Employee of Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Own stock and stock options in Merck

    Legal Proceedings:

    1. NONE

  2. Ellen Snyder, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Merck, Senior Principal Scientist, Biostatistics

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Employee of Merck & Co., Inc.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Own stock and stock options in Merck.

    Legal Proceedings:

    1. NONE

  3. Kerry Budd, BS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck, Clinical Scientist

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Employee of Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Own stock options at Merck

    Legal Proceedings:

    1. NONE

  4. Jill Hutzelmann, MS,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck, Sr. Clinical Scientist

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Yes, employee of Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Merck stock/stock options, 1990 to present

    Legal Proceedings:

    1. NONE

  5. Duane Snavely, MA,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck, Director of Late Development Statistics

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Employee of Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Own stock, and stock options in Merck

    Legal Proceedings:

    1. NONE

  6. Kenneth Liu, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck, Senior Principal Scientist, Biostatistics.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Employee of Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Own stock and stock options at Merck

    Legal Proceedings:

    1. NONE

  7. Christopher Lines, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck, Director Global Scientific and Medical Publications

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Employee of Merck

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Own stock and stock options in Merck

    Legal Proceedings:

    1. NONE

  8. Thomas Roth, PhD and
    9. Scientific Advisory Boards:

    1. Merk, Jazz, Transcept,

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Sleep, Sleep Medicine

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Roth has served as a consultant for Abbott, Accadia, Acogolix, Acorda, Actelion, Addrenex, Alchemers, Alza, Ancel, Arena, AstraZenca, Aventis, AVER, Bayer, BMS, BTG, Cephalon, Cypress, Dove, Eisai, Elan, Eli Lilly, Evotec, Forest, Glaxo Smith Kline, Hypnion, Impax, Intec, Intra-Cellular, Jazz, Johnson and Johnson, King, Ludbeck, McNeil, MediciNova, Merck, Neurim, Neurocrine, Neurogen, Novartis, Orexo, Organon, Otsuka, Prestwick, Proctor and Gamble, Pfizer, Purdue, Resteva, Roche, Sanofi, SchoeringPlough, Sepracor, Servier, Shire, Somaxon, Syrex, Takeda, TransOral, Yanda, Vivometrics, Wyeth, Yamanuchi, and Xenoport

    Speakers' Bureaus:

    1. Purdue

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Transcept, Impax, Linguflex, Apnes

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. David Michelson, MD
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Merck Employee

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Merck stockholder

    Clinical Procedures or Imaging Studies:

    1. Merck employee, Merck would market the drug if approved by regulatory authorities

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Stock and stock options in Merck

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Merck Sharp & Dohme Corp. (W.J.H., E.S., K.B., J.H., D.S., K.L, C.L, D.M.), Whitehouse Station, NJ; and Henry Ford Hospital Sleep Center (T.R.), Detroit, MI.
  1. Correspondence & reprint requests to Dr. Herring: william.herring{at}merck.com
View Full Text

Article usage

Article usage: November 2012 to April 2023

AbstractFullPdfSource
Nov 2012740328Highwire
Dec 2012266469139Highwire
Jan 20137193055Highwire
Feb 20133122436Highwire
Mar 20132561620Highwire
Apr 20133713434Highwire
May 20132442422Highwire
Jun 20131842923Highwire
Jul 2013168810Highwire
Aug 20131681010Highwire
Sep 2013169611Highwire
Oct 20131481315Highwire
Nov 201311477Highwire
Dec 201316469Highwire
Jan 2014142117Highwire
Feb 201415474Highwire
Mar 201419795Highwire
Apr 20141781211Highwire
May 20141661111Highwire
Jun 201414762Highwire
Jul 201414634Highwire
Aug 20143252540Highwire
Sep 20143322932Highwire
Oct 20142961419Highwire
Nov 20142951526Highwire
Dec 20143552122Highwire
Jan 20155413445Highwire
Feb 20156762325Highwire
Mar 20155691618Highwire
Apr 2015349810Highwire
May 20153071110Highwire
Jun 2015294610Highwire
Jul 20151991314Highwire
Aug 2015300710Highwire
Sep 20153061718Highwire
Oct 20152381814Highwire
Nov 201521877Highwire
Dec 201520032Highwire
Jan 201620367Highwire
Feb 20161711610Highwire
Mar 201617596Highwire
Apr 201615739Highwire
May 201613198Highwire
Jun 201612811Highwire
Jul 201613153Highwire
Aug 201615921Highwire
Sep 201613441Highwire
Oct 201613726Highwire
Nov 201612422Highwire
Dec 201614801Highwire
Jan 201719986Highwire
Feb 201715477Highwire
Mar 201714211Highwire
Apr 201714956Highwire
May 201719055Highwire
Jun 2017161116Highwire
Jul 201713016Highwire
Aug 201714394Highwire
Sep 201714285Highwire
Oct 201731214Highwire
Nov 201721221Highwire
Dec 201713610Highwire
Jan 201820894Highwire
Feb 2018165101Highwire
Mar 2018293173Highwire
Apr 2018361167Highwire
May 2018445141Highwire
Jun 2018214155Highwire
Jul 201818211Highwire
Aug 201819646Highwire
Sep 201825584Highwire
Oct 201815145Highwire
Nov 20181701211Highwire
Dec 201814801Highwire
Jan 201915154Highwire
Feb 201938036Highwire
Mar 201925842Highwire
Apr 201921313Highwire
May 201918372Highwire
Jun 201915535Highwire
Jul 201912433Highwire
Aug 2019222158Highwire
Sep 20194032540Highwire
Oct 20192093350Highwire
Nov 201918456Highwire
Dec 201915222Highwire
Jan 202019734Highwire
Feb 2020275106Highwire
Mar 2020527156Highwire
Apr 202022183Highwire
May 202016257Highwire
Jun 202014033Highwire
Jul 202013355Highwire
Aug 202011852Highwire
Sep 2020410109Highwire
Oct 202015141Highwire
Nov 202015022Highwire
Dec 202017325Highwire
Jan 202116222Highwire
Feb 202125674Highwire
Mar 202121022Highwire
Apr 202123512Highwire
May 202116532Highwire
Jun 202111522Highwire
Jul 202114522Highwire
Aug 202118743Highwire
Sep 202132284Highwire
Oct 202121486Highwire
Nov 202123087Highwire
Dec 2021168111Highwire
Jan 202218988Highwire
Feb 2022431116Highwire
Mar 202235769Highwire
Apr 202224311Highwire
May 202213954Highwire
Jun 20228323Highwire
Jul 202212934Highwire
Aug 202213312Highwire
Sep 20221463417Highwire
Oct 2022167119Highwire
Nov 202223324Highwire
Dec 202211286Highwire
Jan 202311485Highwire
Feb 2023108117Highwire
Mar 202318352Highwire
Apr 202313434Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles